Relationship of Lipoprotein Lipase and Hepatic Triacylglycerol Lipase Activity to Serum Adiponectin Levels in Japanese Hyperlipidemic Men

Kobayashi, Junji; Kusunoki, Masataka; Murase, Yuko; Kawashiri, Masa‐aki; Higashikata, Toshinori; Miwa, Kenji; Katsuda, Shoji; Takata, Masaru; Asano, Akimichi; Nohara, Atsushi; Inazu, Akihiro; Mabuchi, Hiroshi

doi:10.1055/s-2005-870318

Cited by 42 publications

(33 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Perhaps the same phenomenon is occurring in this study. Also, we previously reported that in Japanese subjects, HL activity in PHP showed positive correlation with plasma TG levels, which is not inconsistent with the present observation (24).…”

Section: Discussionsupporting

confidence: 71%

A novel method for measuring human lipoprotein lipase and hepatic lipase activities in postheparin plasma

Imamura

Kobayashi

Nakajima

et al. 2008

Journal of Lipid Research

Self Cite

View full text Add to dashboard Cite

The objective of this study was to establish a new lipoprotein lipase (LPL) and hepatic lipase (HL) activity assay method. Seventy normal volunteers were recruited. Lipase activities were assayed by measuring the increase in absorbance at 546 nm due to the quinoneine dye. Reaction mixture-1 (R-1) contained dioleoylglycerol solubilized with lauryldimethylaminobetaine, monoacylglycerol-specific lipase, glycerolkinase, glycerol-3-phosphate oxidase, peroxidase, ascorbic acid oxidase, and apolipoprotein C-II (apoC-II). R-2 contained Tris-HCl (pH 8.7) and 4-aminoantipyrine. Automated assay of lipase activities was performed with an automatic clinical analyzer. In the assay for HL 1 LPL activity, 160 ml R-1 was incubated at 37°C with 2 ml of sample for 5 min, and 80 ml R-2 was added. HL activities were measured under the same conditions without apoC-II. HL and LPL activities were also measured by the conventional isotope method and for HL mass by ELISA. Lipase activity detected in a 1.6 M NaCl-eluted fraction from a heparin-Sepharose column was enhanced by adding purified apoC-II in a dose-dependent manner, whereas that eluted by 0.8 M NaCl was not. Postheparin plasma-LPL and HL activities measured in the present automated method had high correlations with those measured by conventional activity and mass methods. This automated assay method for LPL and HL activities is simple and reliable and can be applied to an automatic clinical analyzer.-Imamura, S., J. Kobayashi, K. Nakajima, S. Sakasegawa The diagnosis of LPL and HL deficiency is based on the lack of their respective enzyme activities in postheparin plasma (PHP) from affected individuals (1). The conventionally available method for measuring LPL and HL activity has been the use of 3 H-or 14 C-labeled trioleoyl glycerol as substrate in the presence of 1 M NaCl or the anti-LPL monoclonal antibody, 5D 2 (10, 11); remaining activity is considered to be HL activity under these conditions. However, this assay procedure is complicated and is not suitable for routine clinical or research work. Methods for measuring LPL or HL protein mass by ELISA in PHP have been developed by several groups, including ours, in the last two decades (10-15). These methods have provided considerable evidence for understanding how the amount of LPL or HL protein changes in variable metabolic disorders. To diagnose LPL or HL deficiency, it is essential to determine the absence of the respective lipase activity in PHP, because there are patients with normal mass and lipase activity for each (1). Very recently, we reported a new and simple assay

show abstract

Section: Discussionsupporting

confidence: 71%

A novel method for measuring human lipoprotein lipase and hepatic lipase activities in postheparin plasma

Imamura

Kobayashi

Nakajima

et al. 2008

Journal of Lipid Research

Self Cite

View full text Add to dashboard Cite

show abstract

“…Though we could not detect a difference in serum insulin concentration between the two patient groups, lipoprotein lipase expression is reported to rise due to high serum insulin concentration in type 2 diabetic patients, and preheparin lipoprotein lipase mass is considered to reflect a portion of whole body lipoprotein lipase production 32) . A positive association of plasma adiponectin concentration with post-heparin LPL activity but not with hepatic lipase activity was reported in healthy subjects and patients with type 2 diabetes 33,34) and hyperlipidemic men 35) . These reports support our findings that HMW-adiponectin activates triglyceride metabolism more than glucose utilization, and accelerates the clearance of very low density lipoprotein remnants via lipoprotein lipase, especially in type1 diabetic patients with a high HMW-adiponectin level.…”

Section: Discussionmentioning

confidence: 99%

HMW-Adiponectin Associates with Triglyceride Concentrations in Type 1 Diabetic Patients

Maruyama

Ishibashi

Araki

et al. 2009

JAT

View full text Add to dashboard Cite

Aim:The objective of this study was to investigate the relation between serum high molecular weight (HMW)-adiponectin concentration and fasting and postprandial blood glycemic and lipid parameters in type 1 diabetic patients. Methods: Type 1 diabetic patients treated with short-acting insulin analogs and healthy volunteers were recruited. The subjects were divided into two groups based on the mean HMW-adiponectin value of 12.2 mg/L: low HMW-adiponectin (men/women 7/2) and high HMW-adiponectin (men/ women 3/8). Blood samples were collected after an overnight fast, and 30 − 180 min after consuming white bread (B) or white bread with butter (BB). Results: Type 1 diabetic patients with high HMW-adiponectin had lower triglyceride and remnant like particle (RLP)-triglyceride concentrations than those with low HMW-adiponectin (p 0.01), and had a higher lipoprotein lipase mass (p 0.01) than healthy subjects (men/women 8/6). After B and BB meals, type 1 diabetic patients with high HMW-adiponectin consistently had lower triglyceride and RLP-triglyceride concentrations for up to 180 min than those with low HMW-adiponectin (p 0.01); however, apoB48 did not differ between these two groups. Fasting and postprandial plasma glucose were higher in both diabetic groups than in healthy subjects (p 0.001), with no significant difference between patient groups. Conclusion: HMW-adiponectin is more strongly associated with very low density lipoprotein remnant metabolism than glucose utilization in type 1 diabetic patients receiving short-acting insulin analogs. J Atheroscler

show abstract

“…Furthermore, gliclazide therapy reportedly lowers TNF-α and increases adiponectin levels [8]. Reduced TNF-α and elevated adiponectin levels correlate with improved insulin resistance, which is thought to be associated with low blood PAI-1 levels [34,35]. Furthermore, glibenclamide and glimepiride carry a higher risk of hypoglycemia thangliclazide [36].…”

Section: Discussionmentioning

confidence: 99%

Effects of sulfonylurea treatment on blood plasminogen activator inhibitor-1 levels in patients with type 2 diabetes mellitus: A network meta-analysis

Ida¹,

Murata²,

Kaneko³

2018

J Diab Res Clin Met

View full text Add to dashboard Cite

Background: To compare the effects ofthree types of sulfonylureas (glibenclamide, gliclazide, and glimepiride) on blood plasminogen activator inhibitor-1 levels in patients with type2 diabetes mellitus, a network meta-analysis of randomized controlled trialswas performed. Methods: A literature search using MEDLINE, the Cochrane Central Register of Controlled Trials, and ClinicalTrials.gov was conducted. Randomized controlled trialsin which the effects of sulfonylureas on blood plasminogen activator inhibitor-1 levels in patients with type 2 diabetes mellitus were evaluated were includes. Outcome assessment included standardized mean differences and 95% confidence intervals. Results: Twelve randomized controlled trials (1,050 subjects) met the inclusion criteria and were included in the network meta-analysis. No significant difference was observedin blood plasminogen activator inhibitor-1 levels after using a placebo compared with those after using glibenclamide, gliclazide, and glimepiride. Blood plasminogen activator inhibitor-1levels were significantly lower after using gliclazide than after using glimepiride (standardized mean difference: -0.52; 95% confidence interval: -0.99%-0.44%). However, no significant difference was observed in blood plasminogen activator inhibitor-1 levels after using glibenclamide compared with those after using gliclazide and glime piride. Conclusions: Regarding the use of sulfonylureas for treating patients with type 2 diabetes mellitus, gliclazide may be preferable because of low blood plasminogen activator inhibitor-1 levels after its use. However, few studies have been published on the use of gliclazide, and the quality of these studies has been generally poor; thus, the results of this study should be interpreted with caution.

show abstract

Relationship of Lipoprotein Lipase and Hepatic Triacylglycerol Lipase Activity to Serum Adiponectin Levels in Japanese Hyperlipidemic Men

Abstract: There was a co-linearity between insulin sensitivity and adiponectin as well as insulin sensitivity and LPL/HTGL activity.

Cited by 42 publications

References 10 publications

A novel method for measuring human lipoprotein lipase and hepatic lipase activities in postheparin plasma

A novel method for measuring human lipoprotein lipase and hepatic lipase activities in postheparin plasma

HMW-Adiponectin Associates with Triglyceride Concentrations in Type 1 Diabetic Patients

Effects of sulfonylurea treatment on blood plasminogen activator inhibitor-1 levels in patients with type 2 diabetes mellitus: A network meta-analysis

Contact Info

Product

Resources

About